Here are five insights:
1. RTI Surgical expects full-year 2018 revenues to hit between $280 million and $290 million.
2. The company anticipates full-year 2018 EBITDA to fall between $32 million and $38 million.
3. The company expects its acquisition of Zyga Technology, announced Jan. 4, will lead to revenue growth.
4. Within the next five years, RTI Surgical plans to boost revenue to more than $500 million.
5. Additionally, the company hopes to double its EBITDA margin to more than 20 percent in the next five years.
More articles on biologics:
7 months deep Andrews Institute stem cell, cartilage regeneration study shows positive results: 5 observations
Baptist Health Spine Center offers stem cell injections to help patients avoid surgery: 5 things to know
Shore Orthopaedic’s Dr. Charles Krome offers stem cell therapy for orthopedic conditions: 4 takeaways
